A human monoclonal antibody blocking SARS-CoV-2 infection
The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19.
|Persistent URL||dx.doi.org/10.1038/s41467-020-16256-y, hdl.handle.net/1765/126755|
Wang, C. (Chunyan), Li, W. (Wentao), Drabek, D.D, Okba, N.M.A, van Haperen, M.J, Osterhaus, A.D.M.E, … Bosch, B.J. (2020). A human monoclonal antibody blocking SARS-CoV-2 infection. Nature Communications, 11(1). doi:10.1038/s41467-020-16256-y